triple negative breast cancer

[Clinical Cancer Research] A large cohort of chemotherapy-naïve triple-negative breast cancer (TNBC), clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME were identified in subsets of PD-L1+ and PD-L1- TNBC.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists showed that a unique anti-human CD81 antibody (5A6) effectively halted invasion of TNBC cell lines. They demonstrated that 5A6 induced CD81 clustering at the cell membrane and implicated JAM-A protein in the ability of this antibody to inhibit tumor cell invasion and migration.

[Nature Communications] The authors studied endocrine immune related adverse events from seven clinical trials across six cancers where atezolizumab was combined with chemotherapies and compared to standard of care.

[npj Breast Cancer] Mesenchymal stem/stromal cells stimulated robust expression of LINC01119 in TNBC cells, which in turn induced suppression of cytokine signaling 5 (SOCS5), leading to accelerated cancer cell growth and tumorigenesis.

[Journal of Nanobiotechnology] Researchers prepared shell-core structure nanoparticles which inhibited tumor growth and angiogenesis in vitro and in MDA-MB-231 tumor-bearing mice via downregulating the sphingosine 1 phosphate receptor 1/phosphorylated signal transducer and activator of transcription 3/vascular endothelial growth factor A axis.

[npj Breast Cancer] The authors focused on the emerging class of RNAs called long non-coding RNAs or lncRNAs and utilized a MSC-supported triple-negative breast cancer (TNBC) progression model to identify specific family members of functional relevance to TNBC pathogenesis.